The 5th Anniversary Central Asian International exhibition «Chemical industry – Chemie Uzbekistan» and the 2nd Uzbek International exhibition of plastics and rubber – «Plastex Uzbekistan 2011» will be held from the 16th till the 18th of November 2011, at the Pavilion 1 of OJSS «Uzexpocentre».

“ITE UZBEKISTAN” is the organizer of the exhibitions

Talking about Uzbekistan, look at this siteif you would need some oils and herbal essentials to take along with you in the tour. Uzbekistan is a safe country and you can enjoy the serenity and the relaxed atmosphere here. Tashkent is the largest city in Uzbekistan. You can definitely plan your next trip to Uzbekistan, either solo or with family.

Though there is no strict dress code to be followed when visiting Uzbekistan, it is important that you do not wear any revealing dresses. The country folks dress conservatively and it is important that you do so as a respect to their culture. Make sure that you pack comfortable shoes that make it easy to walk on the sandy and dry ground. Long skirts and pants and long sleeve shorts with a high neckline can be worn in Uzbekistan.

The exhibitions will feature the following sections:

– Agrochemistry
– Raw and equipment for chemical industry
– Composite materials, glass-fibre plastics
– Grit-tipped blade
– Synthetic rubbers
– Household chemicals
– Keeping and transporting of chemical product
– Chemical technologies, research activities
– Laboratory and analytical equipment, devices
– Technic and equipment for producing plastics and rubbers
– Equipment for primary processing materials
– Reprocessing equipment
– Extruders and extrusion utilities
– Machines for ?????? ??? blown forming
– Machines and equipments for producing tyres
– Auxiliary equipment, forms, matrix
– Raw and auxiliary materials
– Mechanical packer
– Semi-finished product and ready-made goods
– Services in the sphere of producing fibers and rubbers

New technologies and innovations in the sphere of chemical substance, raw and auxiliary equipments will be presented at the exhibitions as well.

Such companies from Austria, Germany, India, China, Poland, Russia, Taiwan, Uzbekistan as: Asian diamond classic; Oybek otchopar plastik; Korting Gmbh; Nigmatjon-rin; Omsk plant of trumpet isolation; Xinjiang huangjin mid-asia engineering technology co., Ltd; Uzkimyosanoat; Tongling nextool; Tingdao plastic; Qingdao leader; Trade and Investment Promotion Department of the Embassy of the Republic of Poland in the Rebublic pf Uzbekistan; King hsing; Coperion Gmbh; Starlinger; Lohia starlinger; Shurtan g

Read More →
Share:

The inaugural Drug Discovery Latin America conference and exhibition will be held in the colourful city of Rio de Janeiro in the days immediately following the world famous carnival.

The purpose of this meeting is to review the status of drug discovery activities in Latin America and to assist its future development. Drug discovery is an important part of medical science. Thissite web speaks about how the medicines developed in the last century were derived from molecules that were naturally occurring. These are products that are found in the natural sources. Itincludes fungi,bacteria and plants. The drugs are first tested on animals and then it goes through the clinical trials. These are tested on healthy individuals to check if the drugs are safe. Business and research leaders from both developed markets and BRIC countries will bring their knowledge and experience to share. Participants will be encouraged to network and explore partnering opportunities.

Full conference passes include admission to all sessions and the exhibition as well as conference documentation.
Lunch, coffee breaks and the drinks reception provide ample time for networking and to continue discussions from the question and answer sessions.

Agenda

Day One – 26 February 2009

Screening

09:00

Using Drug Molecules as Probes and Probe Molecules as Drug Precursors
Ralph Garippa, Research Leader, Roche Discovery Technologies
This talk will highlight some examples of Pharma’s HT screened molecules which became popular commercialized reagents, and some promising molecules which have been published in the public domain (PubMed) as a result of academic screening.

09:30

Title to be Confirmed
Jeremy Caldwell, Director of Cell Based Screening, GNF

10:00

Using in vitro Screening Assays to Profile the Biology of Chemical Entities
John Watson, Director, Pharmacology and Biotechnology, Promega
Profiling of a compound’s impact on cell signaling pathways, ADME properties and cellular toxicity early in the discovery process can help prioritize compounds to help assure the final drug has maximal target activity and minimal off target effects.

10:30

Coffee and Networking in the Exhibition Hall

11:15

Nuclear Receptor Activation Assessment: Improving Safety and Directing Chemistry
Kyle Kramer, Vice President, Business Development, Puracyp
The presentation includes introduction to key nuclear receptors (NR) involved in drug metabolism. The construction and use of stable cell lines with reporter genes is explained. Finally, the utility of these systems in drug safety screening is presented.

11:45

Functional Genome-Wide Screening for Genes that Regulate p53 in Endothelial Cells
Michael Edel, Principle Investigator, Centre of Regenerative Medicine in Barcelona
Angiogenesis requires an increase in endothelial cell proliferation to support an increase in mass of blood vessels. An in vitro cell model has been designed that can be used for screening gene or chemical libraries that regulate endothelial cell proliferation.

12:15

Presentation to be Announced

12:45

Lunch and Networking in the Exhibition Hall

Tropical Disease Drug Development

14:00

Prolyl Oligopeptidase of Trypanosoma cruzi (POP Tc80) : A Target for the Design of New Weapons Against Chagas Desease
Bernard Maigret, CNRS Research Director, LORIA – Nancy University
The group has recently demonstrated that the activity of POPTc80, a prolyl endopeptidase that mediates native collagen and fibronectin hydrolysis, is required for trypomastigotes entry into host cells. Using a tridimentionnel model of this target built from homology modelling, molecular docking and screening assays they were able to identify possible new compounds active against Chagas desease.

14:30

Novel Drug Targets for the Malaria Parasite
Asif Mohmmed, Staff Research Scientist, International Centre for Genetic Engineering and Biotechnology

15:00

Title to be Confirmed
Leila de Mendonça Lima, Senior Researcher and Head of Lab. for Functional Genomics and Bioinformatics, Oswaldo Cruz Foundation, FIOCRUZ

15:30

Coffee and Networking in the Exhibition Hall

16:15

Drug Discovery of Fluorinated Drugs Against Neglected Diseases and HIV/AIDS
Núbia Boechat, Head of R&D Group in Medicinal Chemistry, Oswaldo Cruz Foundation, FIOCRUZ
Organic synthesis of fluorinated compounds in medicinal chemistry against AIDS and neglected diseases; innovation and technological management in public health.

Drug Discovery in Emerging Markets

16:45

Drug Development and Discovery
Christopher Bianca, Professor of Chemistry, Clinical Consultant, Keystone College Academia
This presentation discusses all the relevant information required to develop a new drug or a lead compound drug, from toxicology, to pharmacodynamics, to pharmacokinetics, and all the way to clinical trials including FDA approval.

17:15

Stem Cells in Drug Discovery
Chris Kendrick-Parker, Chief Commercial Officer, Cellular-Dynamics International

17:45

Drinks Reception

Day Two – 27 February 2009

Drug Discovery in Emerging Markets (continued)

09:00

Title to be Confirmed
Marcelo Criscuolo, Executive Director, Bio Sidus

09:30

Ranbaxy’s Quest to Become a Research Based International Pharmaceutical Company
Abhijit Ray, Director, New Drug Discovery Research, Ranbaxy Laboratories
Ranbaxy has worked hard to create physical infrastructure, science base and a sustainable strategy for drug discovery research. How this effort has borne fruit will be discussed.

10:00

Taking Companies from Concept to Market
Paul Morril, Co-Founder, Execute Technologies

10:30

Coffee and Networking in the Exhibition Hall

11:15

Title to be Confirmed
Jose Krieger, Heart Institute (InCor), University of Sao Paulo

11:45

Comparative Proteomics Identification of Diagnostic and Prognostic Biomarkers in Leukemias
Eliana Abdelhay, Head of the Bone Marrow Transplantation Laboratory, National Cancer Institute (INCA)
Through proteomics the group analyzed the modifications in the protein profile of bone marrow MNCs from patients in CML phases and in Imatinib Mesylate treatment. They could identify several putative biomarkers of diagnostic, evolution and treatment response that can be use in drug design.

12:15

NFAT Transcription Factors: A Putative New Target in Cancer
João Viola, Head, Division of Cell Biology, National Cancer Institute (INCA)
The Nuclear Factor of Activated T Cells (NFAT) family of transcription factors is activated upon different stimuli that lead to increased intracellular calcium levels. NFAT proteins regulate genes that control many aspects of malignant cell transformation and tumour development. The group investigates the molecular mechanisms by which NFAT regulate tumour-related events and its involvement in oncogenesis.

12:45

Lunch and Networking in the Exhibition Hall

Natural Products

14:00

ChemBioBank, an Academic Project for Drug Discovery in Latin America
Fernando Albericio, Executive Director, Barcelona Science Park, University of Barcelona
The goal of the Latin American ChemBioBank project (LA-CBB) is to build a chemico-biological database, annotated with both biological and bioinformatic data, addressed to the scientific community and to the pharmaceutical and biotech industries.

14:30

High Content Screens for Novel Antipoxviral Agents: Natural Products to the Rescue
Hakim Djaballah, Director, Memorial Sloan Kettering Cancer Centre
The group have developed and validated a high content assay to screen for compounds that would preferentially block viral entry, viral replication, or viral spread upon infecting cell monolayer seeded in 384-well plates with a recombinant vaccinia virus which expresses karyophilic GFP under the control of a viral early/late promoter.

15:00

Using a Luciferase Based Screening Assay to Identify Traditional Chinese Medicine Targeting Nuclear Hormone Receptors
Chiwai Wong, Principal Investigator, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences
Since the activities of nuclear hormone receptors (NHRs) are regulated by small molecule compounds and that Traditional Chinese Medicine (TCM) extracts contain a diverse array of naturally derived chemicals, the group investigated if selective TCM extracts modulate the activities of NHRs.

15:30

Coffee and Networking in the Exhibition Hall

16:15

Bourreria huanita Flowers, a New Antidepressant?
Miguel Torres, Biological Chemist, University of San Carlos
Ethnobotanical and pharmacological studies have preliminarily demonstrated an antidepressant effect in ethanolic extract of dried Bourreria huanita (Boraginaceae) flowers from Guatemala. It’s possible this natural product contains a medically useful molecule and funding is required to continue the chemical analysis and elucidation.

16:45

Post Absorption and Metabolism Compounds: A New Approach to Discover Drug Candidates from Chinese Herbal Medicine
William Jia, VP Research and Associate Professor, Shanghai Innovative Research Centre/University of British Columbia
In a recent study the group has isolated compounds post absorption/metabolism (PAM) of orally taken ginseng. The study showed that those compounds are highly active for neuroprotection and anti-depression.

Read More →
Share:

Genentech this week will step up its efforts to keep the drug Avastin available as a treatment for breast cancer, urging the Food and Drug Administration to give it one more chance to prove the medicine works.

At a hearing on Tuesday and Wednesday in suburban Washington, Genentech will ask the F.D.A. to reconsider its proposal last December to revoke the approval of Avastin for breast cancer on the grounds that new studies did not confirm that the drug helped patients.

Breast cancer can be treated if detected at an early stage. The early signs of breast cancer are a mass or lump on the breast, swelling in a part or all of the breast, dimpling or skin irritation , pain in the nipple or breast, scaly or red breast skin, and discharge from the nipple. You can also treat varicose vein with Varikosetteif diagnosed early.

Genentech’s approach seems intended to broaden the terms under which Avastin can remain available. The company is arguing that even if the F.D.A. reaffirms that data do not support Avastin’s effectiveness, the approval should be retained while Genentech does one more clinical trial. Avastin has remained available for breast cancer pending the appeal process.

Avastin was put on the market under an accelerated program begun in the early 1990s that allows drugs for serious diseases to be approved with less than the usual amount of evidence, subject to further studies. Dozens of drugs have been approved this way, and in at least a couple of cases approvals have been withdrawn. But this is the first time the F.D.A. will hold a hearing to consider a company’s appeal.

The debate over Avastin has evoked passions on both sides among those involved in women’s health issues. Some patient advocates argue that the F.D.A. needs to revoke the approval to maintain the integrity of the accelerated process and to ensure that cancer patients receive drugs that work.

But some breast cancer patients are expected to testify at the hearing that the drug should be kept available because it helps some women, even if not all.

“It’s so depressing to think that a federal agency can make a decision that can potentially cause me to die,” said Crystal Hanna, 35, a mother of two from Parkersburg, W.Va., who said Avastin has kept her cancer under control for almost a year.

The public comments sent to the F.D.A. before the hearing at its campus outside Washington, overwhelmingly support retaining the approval. Many of them, using virtually identical language, cite the case of Ms. Hanna, who drafted a comment for friends that circulated widely on the Internet.

Even if approval as a breast cancer treatment is ultimately rescinded, Avastin will retain approval to treat lung, colon, kidney and brain cancers. So doctors will be able to use it “off label” to treat breast cancer. But insurers might no longer pay for it for that use, putting the drug, which can cost $88,000 a year, out of reach for many women.

The Avastin issue has become caught up in the politics of overhauling health care, with some critics saying the decision not to pay for it represents rationing and others saying that Medicare should not pay for a drug that does not work. The F.D.A. maintains that it is not permitted to consider costs.

The ultimate decision will be made by the F.D.A. commissioner, Dr. Margaret A. Hamburg, who appears to have some latitude. The rules say that the F.D.A. “may” revoke the approval of a drug, but does not have to.

“Even where F.D.A. determines that confirmatory trials do not establish clinical benefit, withdrawal is not required and instead should be based on the public health considerations that motivate the accelerated approval statute,” Genentech argues in a summary of its arguments filed before the hearing.

But the F.D.A.’s drug division views the company’s request as a stalling tactic. “How many bites of the apple do you get?” Dr. Richard Pazdur, the director of the agency’s oncology drug division, said in an interview at a cancer conference early this month.

The agency, in a summary of its arguments, says that because it has already determined that the benefits of Avastin do not outweigh the risks, retaining the approval while the new study is conducted “would not be in the interest of the public health and would jeopardize the integrity of the accelerated approval program.”

Genentech and its parent company, Roche, could lose as much as $1 billion in annual sales if the breast cancer approval were revoked. Already Avastin sales for treatment of breast cancer have started declining. The drug is the world’s best-selling cancer drug, with sales last year of roughly $7 billion.

The F.D.A. approved the drug for advanced breast cancer in February 2008, after one clinical trial showed that combining Avastin with another drug, paclitaxel, delayed the median time before tumors worsened by 5.5 months, compared with using paclitaxel alone. But the women who got Avastin did not live significantly longer than those who got only paclitaxel, which is also known by the brand name Taxol.

Subsequent trials, in which Avastin was combined with different chemotherapy drugs, showed a much smaller delay in tumor progression, ranging from less than 1 month to 2.9 months. And again there was no improvement in survival for those receiving Avastin.

Based on those results and on the fact that Avastin has some life-threatening side effects, including bowel perforation and hemorrhaging, the F.D.A.’s cancer drug advisory committee voted 12 to 1 last July that the approval for the treatment of breast cancer be revoked.

The hearing this week will be before the same committee, which will make recommendations to the F.D.A. commissioner. Of the six voting committee members expected to attend, five voted to revoke the approval last July. The sixth was not at that earlier meeting. Since the data have not changed, Genentech, in the summary of its arguments, concedes it is not likely to change the committee’s mind about the benefits of Avastin.

Instead it will argue that the drug with which Avastin is combined matters. Therefore, the company should be given a chance to do another trial in which Avastin is combined with paclitaxel, as in the original trial that led to the drug’s approval.

Read More →
Share:

Inpharmatica Ltd today announces that Wyeth Pharmaceuticals, a division of Wyeth has licensed Admensa Interactive, Inpharmatica’s platform of predictive drug absorption, distribution, metabolism and excretion models and compound prioritization tools.

Wyeth will use Admensa Interactive to support compound selection and optimization in its drug discovery projects.

This new license, agreed after an extensive evaluation, further demonstrates the value that Admensa Interactive brings to pharmaceutical and biotechnology companies.

Under the terms of the agreement, Wyeth will receive a multi-site license to Admensa Interactive.

The load on the health care system is immense. Many entrepreneurs are venturing into this space. The healthcare business could also be a great idea for your start-up. The healthcare industry is, however, sensitive and you should make sure that you embark on this journey with care.

You know of the immense potential that this business has to offer. You may also decide to make healthcare supplements like Bioretinwhich is an anti-ageing cream.

The industry is prosperous and you being a businessman may want to tap this space. The healthcare industry also has a genuine gesture towards philanthropy. Now that you are determined you should weigh the issues and be prepared before you get into the healthcare sector. Have a strategy that is well thought of and well developed.

Admensa Interactive combines predictive models with a desktop interface combining model output with project data from other sources.

This integrated selection and visualization platform drives effective decisions on the best compounds on which to move forward against project criteria.

Admensa Interactive is a major component of Inpharmatica’s range of gene-to-candidate technologies which integrate biology and chemistry-based drug discovery activities.

Inpharmatica’s platform ranges from target selection based on druggability, through rapid identification of hits to selection of high quality leads and pre-clinical candidates, which are prioritized on the basis of good drug-like characteristics.

“We are delighted that Wyeth has opted for a broad deployment of Admensa Interactive in support of its drug discovery projects,” said Matt Segall, Head of the Admensa Business Unit of Inpharmatica.

“The strong uptake of this product by top pharma and biotech companies is a testimony to the unique capabilities it provides for compound optimization.”

Further Information: http://www.inpharmatica.com/admensa.htm

Read More →
Share:


*** PRESENT A POSTER *** Deadline 2 September 2005. If you would like the opportunity to present your poster at this event, please email abstracts to: v.colcombet@selectconferences.com – LIMITED SPACE AVAILABLE

The inaugural conference on Advances in Microarray Technology provides an in-depth analysis of the current thinking and latest technologies within this field.

Technology is a big boon to the society. It has been beneficial to humans in various ways. In the medical field, technology is used to treat the sick patients more effectively. It also helps to save lives and combat harmful bacteria. Technology brought to us Artrovexwhich is an amazing product that helps to treat joint pain. Technology has increased productivity in almost every industry in the world.

This highly targeted event has captured the imagination of the industry and has proved to be very popular so far. Don’t miss this opportunity to network with the leading institutions from around the world.

Register from only €310

Organisations already confirmed:

Adhesives Research Ireland Ltd – Affymetrix, Inc. – Akonni Biosystems Inc. – Arrayjet – Asterand Inc – Auburn University – Avalon Pharmaceuticals – BioChannel Partners Ltd – BioDiscovery, Inc. – Bioeagles Ltd – Cambridge Life Sciences – Centre de recherché en Infectiologie de l’Universite Laval – Cytomyx – DKFZ Heidelberg – Dynal Biotech Ltd. – Epitome Biosystems, Inc. – European Institute of Oncology – Fluidigm Corp. – Free University of Brussels – Functional Genomics Center Zurich – GSF Research Centre, BIOP – Imperial College London – Innogenetics NV – InsightFaraday Partnership – Institut Curie – Institut des Hautes Etudes Scientifiques & Interdisciplinary Research Institute – Invitrogen Ltd. – KREATECH Biotechnology – Lund University – Max Planck Institute for Marine Microbiology – Metis Biotechnology Ltd – Netherlands Vaccine Institute – NMI Natural and Medical Sciences Institute at the University of Tuebingen – Novartis Pharma AG – PamGene International – Pfizer Inc. – Protagen AG – Royal Insti tute of Technology (KTH) – Schott Janaer Glas GmbH – Serono International – Sterne Kessler Goldstein & Fox – University Medical Center Hamburg-Eppendorf – University of Edinburgh – University of Manchester – University of Pretoria – University of Wageningen – University of Washington – Veterinary Laboratories Agency – ViaLogy Corp. – Whatman/Schleicher & Schuell – Yole Developpement

Exhibitors already confirmed

– Arrayjet – Corporate Sponsor
– Cytomyx – Corporate Sponsor
– Invitrogen Corporation – Corporate Sponsor
– Tecan – Corporate Sponsor
– Agilent Technologies
– Operon
– RZPD
– Davin Optronics Ltd
– GRI
– Genomic Solutions
– KREATECH Technologies
– Miltenyi Biotec GmbH
– Parallabs Ltd
– Schott Nexterion
– Scienion AG
– Sigma-Aldrich
– Topspin APS

Further details available through the following links:

Full Agenda http://www.selectbiosciences.com/conferences/AMT/Detailed_Agenda.aspx

Conference Brochure http://www.selectbiosciences.com/conferences/files/AMT%20brochure.pdf

Registration – Register by August 31st and SAVE UP TO €200 https://selectbiosciences.com/conferences/AMT/booking/register.aspx

===============================================================================================

Agenda Sessions and Speakers:

Day One: 11th October

08:30 THE BIOCHIP BUSINESS
Chaired by Dr. Arndt Benecke, Institut des Hautes Etudes Scientifiques & Interdisciplinary Research Institute

  • Dr. Geraldine Andrieux, Yole Developpement
  • Dr. Jorge Goldstein, Sterne Kessler Goldstein & Fox

————————————

10:30 BIOINFORMATICS
Chaired by Dr. Arndt Benecke, Institut des Hautes Etudes Scientifiques & Interdisciplinary Research Institute

  • Dr. Arndt Benecke, Institut des Hautes Etudes Scientifiques & Interdisciplinary Research Institute
  • Speaker to be confirmed, ViaLogy Corp.
  • Dr. Bruce Hoff, BioDiscovery, Inc.
  • Dr. Eugene Novikov, Institut Curie

————————————

14:05 TISSUE & CELL-BASED MICROARRAYS
Chaired by Prof. Guido Sauter, University Medical Center Hamburg-Eppendorf

  • Prof. Guido Sauter, University Medical Center Hamburg-Eppendorf
  • Dr. Xavier Gidrol, CEA
  • Dr. Roberta Carbone, European Institute of Oncology
  • Dr. Roderick Westrop, Cytomyx
  • Dr. Juan J. Miret, Pfizer Inc.

Day Two: 12th October

08:30 PROTEIN MICROARRAYS: TECHNOLOGY AND APPLICATIONS PART I

Chaired by Prof. Mathias Uhlen, Department of Biotechnology, Albanova University Center, Royal Institute of Technology (KTH), Stockholm

  • Dr. John L. Tonkinson, Epitome Biosystems, Inc.
  • Dr. Ulrike Korf, DKFZ Heidelberg
  • Keynote Speaker – Prof. Mathias Uhlén, Department of Biotechnology, Albanova University Center, Royal Institute of Technology (KTH)
  • Dr. Jens Beator, Whatman/Schleicher & Schuell
  • Dr. Christer Wingren, Lund University
  • Dr. Jeremy Gillespie, Invitrogen Ltd.

————————————

13:55 PROTEIN MICROARRAYS: TECHNOLOGY AND APPLICATIONS PART II

Chaired by Dr. Colin Campbell, The University of Edinburgh

  • Keynote Speaker – Dr. Thomas Joos, NMI Natural and Medical Sciences Institute at the University of Tuebingen
  • Dr. Mike Bunce, Dynal Biotech Ltd.
  • Dr. Charles Daitch, Akonni Biosystems Inc.
  • Dr. Mohammed Zourob, University of Manchester
  • Dr. Colin Campbell, The University of Edinburgh
  • Mr. Duncan J Hall, Arrayjet

Day Three: 13th October

08:30 ADVANCES IN DNA MICROARRAYS
Chaired by Dr. Wolfgang Budach, Novartis Pharma AG

  • Dr. Wolfgang Budach, Novartis Pharma AG
  • Dr. Tarif Awad, Affymetrix, Inc.
  • Dr. Kris Pappaert, Free University of Brussels
  • Dr. Ted van der Lende, KREATECH Biotechnology
  • Dr. Katrin Steinmetzer, Schott Janaer Glas GmbH
  • Dr. Arnold Vainrub, Auburn University

————————————

13:55 MICROFLUIDIC ARRAYS
Chaired by Prof. Martin Dufva, Dept. of Micro & Nanotechnology, Technical University of Denmark

  • Dr. Michael Lucero, Fluidigm Corp.
  • Dr. Rinie van Beuningen, PamGene International
  • Dr. Koen de Smet, Innogenetics NV
  • Dr. Regis Peytavi, Centre de recherché en Infectiologie de l’Universite Laval, Quebec

===============================================================================================

Full Agenda available online at: http://www.selectbiosciences.com/conferences/AMT/Detailed_Agenda.aspx

Preconference Training Course – Applications of Microarrays

10 October 2005

Who should attend?
The course will be suitable for scientists, technicians and engineers. It will be helpful to be familiar with DNA, RNA and proteins to follow the material presented. The course has been designed for people considering working with microarrays and for those who are currently working with some applications of microarrays but want a broader view of additional opportunities.

Course tutor:
Prof. Martin Dufva, University of Denmark.

Full course details: http://www.selectbiosciences.com/conferences/AMT/Training_Course.aspx

===============================================================================================

PRESENT A POSTER – Deadline 2 September 2005. To apply for the opportunity to present at this event, please email abstracts to: v.colcombet@selectconferences.com

In order to ensure the widest possible audience for our speakers, registration fees start at just €310, making this conference an absolute must if you want to see the latest research and equipment in microarray technology whilst networking with your peers.

Best regards
Virginie Colcombet
Conference Manager

Read More →
Share:

WEDNESDAY, Aug. 17 (HealthDay News) — Researchers have found an antibody that might someday be useful in identifying women who have a higher risk of ovarian cancer, or possibly diagnosing early ovarian cancer.

Click here to find out more!

This particular antibody, which was detected in blood, develops as an immune system response to a protein called mesothelin. This protein is present in advanced ovarian cancer. Although mesothelin is found in normal tissue, it’s found in abundance in ovarian cancer cells.

The current study found that infertile women, who are known to have an increased risk of ovarian cancer, were more likely to have the mesothelin antibody. The researchers also found that women with ovarian cancer were more likely to have this antibody.

The common reason for female infertility is the failure to ovulate. This happens in around 40% of women who suffer from issues with infertility. Not being able to ovulate could be because of many reasons. It could be because of a gynaecological  or ovarian condition. It could also be because of POI or primary ovarian insufficiency or PCOS which is polycystic ovary syndrome. If the woman also faces pain or irritation when urinating she can try out Urotrin.

“We’re taking a novel approach to try to identify earlier biomarkers of ovarian cancer by looking at high-risk women,” said study author Judith Luborsky, a professor of pharmacology, obstetrics and gynecology, and preventive medicine at Rush University Medical Center in Chicago.

“This study found that there are antibodies to mesothelin circulating in women that have infertility,” noted Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. Exactly what these findings mean isn’t yet clear, however. “Are these women who will develop ovarian cancer? Are these antibodies related to infertility? This research gives us some clues, and leads to many more questions,” he said.

As for an individual woman who’s currently concerned about ovarian cancer, Lichtenfeld said, “I would be very cautious about drawing any conclusion about the meaning of an elevated antibody level in an individual woman.”

Results of the study will be published Aug. 17 in the online version of the journal Cancer Epidemiology, Biomarkers & Prevention.

Almost 22,000 American women are diagnosed with ovarian cancer each year, and more than 15,000 women die each year as a result of this disease, reports the American Cancer Society.

Most women who develop ovarian cancer aren’t diagnosed until the disease is advanced. If it’s found early, ovarian cancer has a five-year survival rate of 94 percent, according to the cancer society. Two tests that experts hoped would help change that — a combination of transvaginal ultrasound and a blood test for CA-125, a marker associated with ovarian cancer — haven’t reduced a woman’s risk of dying from ovarian cancer, according to a recent study in the Journal of the American Medical Association.

Luborsky and her colleagues wanted to try to find a way to detect early cancer or a screening test for who’s at high risk for ovarian cancer before the cancer develops. Testing for mesothelin wouldn’t work, because it isn’t found at high levels until the cancer is advanced.

So, instead of looking for mesothelin, the researchers looked at a group of 109 infertile women, 28 women with ovarian cancer, and 24 women with benign ovarian cysts or tumors to see if these groups had antibodies to mesothelin. They also compared the three groups of women to healthy women to see if mesothelin antibodies were present.

Significant levels of mesothelin antibodies were found in women with ovarian cancer and in women with unexplained infertility or women who were infertile due to premature ovarian failure or ovulation problems. Women who were infertile due to endometriosis didn’t have significant levels of mesothelin antibodies, according to the study. Healthy women, and women with benign ovarian growths also didn’t have significant levels of mesothelin antibodies, the investigators found.

“There’s a lot more we have to learn, but our aim would be for a screening test that could improve detection,” said Luborsky.

Read More →
Share:

Scientists have worked out how caffeine might protect against certain skin cancers – a finding that could lead to better sunscreens.

The research, conducted in mice, suggests that caffeine changes the activity of a gene involved in the destruction of cells that have DNA damage and are therefore more likely to become cancerous. The scientists said this may lead to new ways of preventing skin cancer, though other experts cautioned that it did not mean coffee lovers were better protected against the disease.

Skin cancer is a common disease. According to Cancer Research UK, around 100,000 cases of non-melanoma were registered in the UK in 2008, and just under 12,000 cases of the more dangerous malignant melanoma.

The melanoma pimple looks like a brown, red or a skin coloured bump. Many doctors could misdiagnose it as a pimple and consider it to a blemish that is harmless. If the doctor however has diagnosed that you have heraing issues then try out Calminax. So the bump begins it look similar to a blister or bubble on the skin and this starts to grow after the first three weeks.

These cancers can be caused by over-exposure to ultraviolet light from the sun, which can damage the DNA of skin cells, leading to errors when the cells divide.

The overall protective role of caffeine against cancers has been noted in previous studies, but Allan Conney of the department of chemical biology at Rutgers University in New Jersey wanted to find the specific molecular mechanisms behind it. He suspected that the response might involve a gene called ATR, which is suppressed when caffeine molecules are around. This suppression encourages the death of DNA-damaged cells.

Conney tested the idea by creating genetically modified mice whose ATR genes were deficient and exposing them to ultraviolet light until they developed skin cancer. After 19 weeks of UV exposure, he found that these mice developed 69% fewer tumours than those that had fully functioning ATR genes. In addition, tumours in the GM mice developed three weeks later than in standard mice.

After 34 weeks of UV exposure, all the mice had developed tumours, mainly a type of non-melanoma cancer called squamous cell carcinoma (SCC). The results were published on Monday in the Proceedings of the National Academy of Sciences.

“All of this suggests the possibility that caffeine, possibly

, would have an inhibitory effect on sunlight-induced skin cancer,” said Conney. “In addition to the effects on the ATR pathway, caffeine also has sunscreening properties.”

SCCs are less common than the other type of non-melanoma cancer, called basal cell carcinomas, but it’s the former that are more dangerous. “People rarely die from basal cell carcinomas, but you need more invasive cutting to get it out,” said Conney. “There’s more disfiguration with basal cell than squamous cell. It’s the squamous cell cancers that can metastasise and are more dangerous.”

Jessica Harris, a health information manager at Cancer Research UK, pointed out that Conney’s study examined how caffeine affected genes when it was directly applied to the skin, rather than ingested. “It didn’t look at the effects of drinking coffee, so doesn’t tell us whether or not this could reduce the risk of skin cancer,” she said.

Studies looking at coffee consumption and cancer in large groups of people have provided mixed results, she added. “Some have found that coffee drinking may slightly reduce the risk of certain types of cancer, but the evidence is not yet strong enough to be certain, and these effects tend to be seen among people who drink very large amounts.”

The best way to reduce the risk of skin cancer, said Harris, “is to enjoy the sun safely, taking care not to burn by using a combination of shade, clothing and sunscreen.”

Dot Bennett, a professor of cell biology at St George’s, University of London, said that any move to add caffeine or related molecules to sunscreens should be undertaken with care. “First one might want to check there is no adverse effect of caffeine on the incidence of other cancers, especially melanoma (pigmented skin cancer), which kills over four times as many people as [squamous cell carcinoma]. But caffeine lotion might promote tanning a little, since this family of molecules stimulates pigment cells to make more pigment.”

Read More →
Share:

In men with elevated prostate specific antigen (PSA), an investigational urine test can detect and stratify prostate cancer, researchers reported.

Look out for the early signs of prostate cancer. These include pain and burning when urinating. One also faces difficulty when urinating and there is a frequent urge to urinate at night. There is loss of bladder control and one also observes blood in the urine and semen. If you however are also experiencing pain in the joints then try out Levasan Maxx

The test is based on the detection of a gene fusion that is specific to prostate cancer, combined with another marker, according to Arul Chinnaiyan, MD, PhD, of the University of Michigan Medical School in Ann Arbor, and colleagues.

Stratifying patients by the combined marker identified groups with markedly different risks of cancer, high-grade cancer, and clinically significant cancer on biopsy, Chinnaiyan and colleagues reported online in Science Translational Medicine.

The noninvasive test could allow some men with elevated PSA to avoid a needle biopsy, the researchers noted.

“Many more men have elevated PSA than actually have cancer but it can be difficult to determine this without biopsy,” Chinnaiyan said in a statement. “The hope is that this test could be an intermediate step before getting a biopsy.”

The fusion at the heart of the test involves the genes transmembrane protease, serine 2 (TMPRSS2), and v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG).

The fusion appears in about half of all prostate cancers, Chinnaiyan and colleagues noted, but when it appears it is almost 100% specific for malignancy.

In a series of experiments, the researchers showed that the fusion gene was associated with indicators of clinically significant cancer at biopsy and prostatectomy.

The indicators included tumor size, high Gleason score at prostatectomy, and upgrading of Gleason grade at prostatectomy, they reported.

But because the fusion gene is not universally present, the researchers created a model that combined it and the prostate cancer antigen 3 (PCA3) gene.

In 1,065 men who underwent biopsy, the researchers used the model to stratify men into three groups – lowest, intermediate, and highest levels of the combined genes.

They found that the groups had distinctly different patterns of risk. Specifically:

  • 363, 346, and 356 men were in the lowest, intermediate, and highest score groups, respectively – or 34%, 32% and 33%.
  • Biopsy resulted in a cancer diagnosis in 21%, 43%, and 69% of men in the lowest, intermediate, and highest groups, respectively. The difference between the low and high groups was significant at P<0.001.
  • 7%, 20%, and 40% of men in the lowest, intermediate, and highest groups were diagnosed with cancer that had a Gleason score of greater than 6. The difference between the low and high groups was again significant at P<0.001.
  • Of the 966 men with enough information to determine the Epstein criteria for significance of cancer on biopsy, 15%, 33%, and 61% of men in the three groups, respectively, had Epstein-criteria-defined significant cancer.

The researchers cautioned that the test remains investigational. As well, they noted, most of the men studied so far have been Caucasian, so that additional study is needed to see if the results apply more broadly.

Read More →
Share:

On behalf of GTCbio and the 2016 Advisory Board, you are invited to the CRISPR & Genome Engineering Conference which takes place May 26-27, 2016 in Boston, MA. This meeting is part of The Genomics & Big Data Summit and will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and discuss the most recent advances in CRISPR & Genome Engineering.

Organizations invest into big data heavily. It helps them to make quick decision that is also agile. This way they stay competitive in the industry. Big data helps in acquiring and retaining customers. Every business depends on its customers and no business can be successful without a solid customer base. Even with an existing customer base a business needs to make sure that it is part of the competition. If the business is slow to learn and is not able to offer what the customer wants then it will end up offering services and products of a poor quality. This is in turn will lead to a loss of clients and will cause an effect on the business. Thepagetalks about some new and innovative products that helps one to get in shape.

Leading researchers will present on hot topics such as: therapeutic applications of CRISPR and genome engineering, discovery and mechanisms of CRISPR systems, and will discuss updates on current CRISPR technologies and techniques. In addition to scientific talks, dedicated networking sessions will allow attendees to better dialogue on how CRISPR & Genome

Engineering will continue to impact biomedical research.

Sessions include:
I. Therapeutic Applications of CRISPR & Genome Engineering
II. Advances in CRISPR-Cas9 Specificity
III. Discovery and Mechanisms of CRISPR Systems
IV. Update: Current CRISPR Technologies & Techniques
V. CRISPR Regulation of Gene Expression
We look forward to seeing you at the conference!

Conference Dates: May 26-27, 2016

Read More →
Share:

Vienna, Austria, August 31 – September 4, 2008
The EFMC-ISMC 2008 Symposium is organized by the Austrian Chemical Society on behalf of the European Federation for Medicinal Chemistry (EFMC).

This symposium is recognized worldwide as one of the leading Medicinal Chemistry meetings, as proven by its large international attendance, which varies between 1200 and 1500 participants from all over Europe, but also from the United States and Asia.

The Symposium will focus on important new scientific and technological developments in the drug discovery process; particularly those relevant to medicinal chemistry.

To discover a drug first the candidate has to be identified. It also involves characterization, synthesis, assays and screening for the therapeutic efficacy. Once the compound shows its own value when the test are performed, the process of drug development starts. This is done before any clinical trials. There have been some drugs that have been discovered accidently in the past. A very amazing supplement that has been discovered is LumiSkinwhich is an anti-ageing supplement.

The meeting will create an environment for in-depth, informed discussions highlighting the importance of medicinal chemistry in the pharmaceutical industry, academia and drug research. It will also provide opportunities to re-emphasise the crucial position of medicinal chemistry in the drug discovery process and its pivotal role in linking and exploiting the associated biological sciences. Therefore, ISMC-2008 intends to create a forum for all scientists interested in medicinal chemistry and related fields.

Programme

Plenary Lectures

Dr. Magid ABOU-GHARBIA
(WYETH RESEARCH, Princeton, United States)

Prof. Chris DOBSON
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

Prof. Paul HERRLING
(NOVARTIS INTERNATIONAL, Basel, Switzerland)

Prof. Barbara IMPERIALI
(MASSACHUSETTS INSTITUTE OF TECHNOLOGY, Cambridge, United States)

Prof. Steven V. LEY
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

GlaxoSmithKline Award forOutstanding Achievement in the Field of Chemical Biology
EFFMC Award Lectures

The Nauta Award for Pharmacochemistry

The UCB-Ehrlich Award for Excellence in Medicinal Chemistry

The Prous Institute-Overton and Meyer Award for Technologies in Drug Discovery
1. Novel Lead Finding Approaches 2. Chemistry Strategies to Reduce Attrition in Drug Discovery 3. Emerging Drugs

Session Chair
Dr. Hans-Ulrich STILZ
(SANOFI-AVENTIS, Frankfurt/Main, Germany)
Title to be determined
Dr. Jeff BLANEY
(STRUCTURAL GENOMIX, San Diego, United States)
Title to be determined
Prof. Roderick E. HUBBARD
(UNIVERSITY OF YORK, York, United Kingdom)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Geoffrey STEMP
(GLAXOSMITHKLINE, Harlow, United Kingdom)
From Fragment to Clinic
Dr. David REES
(ASTEX THERAPEUTICS, Cambridge, United Kingdom)
Chemical Strategies for Successful Clinical Development
Dr. Christopher N. JOHNSON
(GLAXOSMITHKLINE, Harlow, United Kingdom)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Bernd RIEDL
(BAYER HEALTHCARE, Wuppertal, Germany)
The Discovery and Development of Rivaroxaban
Dr. Susanne ROEHRIG
(BAYER HEALTHCARE, Wuppertal, Germany)
The Discovery and Development of a Selective PI3K-Alpha Inhibitor
Dr. Carlos GARCIA-ECHEVERRIA
(NOVARTIS PHARMA, Basel, Switzerland)
Discovery of TMC278: a Next Generation NNRTI Drug, Highly Active against Human Immunodeficiency Virus Type-1
Dr. Jérôme GUILLEMONT
(JOHNSON & JOHNSON PRD, Val de Reuil, France)

4. Kinase Selectivity-Is it Necessary? (ACS) 5. Predictive ADME/Tox Methods: What to Apply When? 6. Macromolecular and Polymeric Drugs

Session Chair
Prof. David ROTELLA
(WYETH RESEARCH, Princeton, United States)
Title to be determined
Dr. Dennis POWELL
(WYETH RESEARCH, Pearl River, United States)
Title to be determined
Dr. Louis LOMBARDO
(BRISTOL-MYERS SQUIBB, , United States)
Title to be determined
Dr. Andrew THOMAS
(ASTRAZENECA R&D, Macclesfield, United Kingdom)

Session Chair
Dr. Scott BOYER
(ASTRAZENECA, Mölndal, Sweden)
Predictive ADME: Examples from the Real World
Dr. Andrew Mark DAVIS
(ASTRAZENECA R&D, Loughborough, United Kingdom)
Virtual Methods for Predicting Off-Target Pharmacology
Dr. Jordi MESTRES
(IMIM AND UNIVERSITAT POMPEU FABRA, Barcelona, Spain)
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Abraham J. DOMB
(HEBREW UNIVERSITY OF JERUSALEM, Jerusalem, Israel)
Keynote
to be selected
Title to be determined
Dr. Ronit SATCHI-FAIRANO
(TEL AVIV UNIVERSITY, Tel Aviv, Israel)
Oral communication
to be selected from submitted abstracts

7. Fragment-Based Drug Discovery (ACS)  8. Imaging Ligands and Biomarkers (EUFEPS) 9. Natural Products as Starting Points in Drug Discovery

Session Chair
Dr. Jeffrey ALBERT
(ASTRAZENECA, Wilmington, United States)
Building the Perfect Beast: Designing a Fragment-Based Drug Discovery Paradigm
Dr. Edward ZARTLER
(MERCK RESEARCH LABORATORIES, Rahway, United States)
Fragment-Based Discovery: What Has it Achieved so far?
Dr. Alexander ALEX
(PFIZER, Sandwich, United Kingdom)
Fragment-Based Methods and the Discovery of BACE-1 Inhibitors for Alzheimer’s
Dr. Jeffrey ALBERT
(ASTRAZENECA, Wilmington, United States)

Session Chair
Prof. Pia VUORELA
(ÅBO AKADEMI UNIVERSITY, Turku, Finland)
Fluorometry and FRET in Measuring Biomarkers and Monitoring Cell Signaling Cascade
Dr. Ilkka HEMMILA
(PERKINELMER LIFE SCIENCES, Turku, Finland)
Mass Sensitive Ligands Useful for Biomarker Discovery and Validation
Dr. Peter SCHULZ-KNAPPE
(PROTEOME SCIENCES, Cobham, United Kingdom)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Erden BANOGLU
(GAZI UNIVERSITY, Ankara, Turkey)
Natural Products as Tools to Identify Novel Drug Targets and Novel Therapeutic Interventions
Dr. Gunda I. GEORG
(UNIVERSITY OF MINNESOTA, Minneapolis, United States)
How to Use The Structural Diversity of Natural Products for Drug Discovery
Dr. Philipp KRASTEL
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Oral communication
to be selected from submitted abstracts

10. Novel Approaches for Treatment of Neurodegenerative Diseases 11. Type 2 Diabetes: The Incretin System 12. Progress in COPD and Asthma Therapy

Session Chair
Dr. Magid ABOU-GHARBIA
(WYETH RESEARCH, Princeton, United States)
Title to be determined
Prof. Hilal A. LASHUEL
(EPFL – ECUBLENS, Lausanne, Switzerland)
Title to be determined
Dr. Steve JACOBSEN
(WYETH RESEARCH, Princeton, United States)
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Koen AUGUSTYNS
(UNIVERSITY OF ANTWERP, Antwerp, Belgium)
Discovery of Sitagliptin and Rational Design of Other Novel DPP-4 Inhibitors
Dr. Tesfaye BIFTU
(MERCK & CO., Rahway, United States)
Peptidic and Nonpeptidic Glucagon-Like Peptide 1 Receptor Agonists
Dr. Jesper LAU
(NOVO NORDISK, Maaloev, Denmark)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Matthias GRAUERT
(BOEHRINGER INGELHEIM, Biberach, Germany)
Recent Developments in CCR3 Antagonists
Dr. George V. DE LUCCA
(BRISTOL-MYERS SQUIBB, Princeton, United States)
Discovery of Potent and Highly Isoform Selective PI3Kg Inhibitors
Dr. Thomas RÜCKLE
(MERCK SERONO, Geneva, Switzerland)
Oral communication
to be selected from submitted abstracts

13. Allosteric Modulation and GPCR Drug Discovery 14. Oncology 15. Immunology & Immunomodulation

Session Chair
Prof. Rob LEURS
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)
The Potential of Allosteric Modulation for GPCR Drug Discovery
Prof. Arthur CHRISTOPOULOS
(MONASH UNIVERSITY, Clayton, Australia)
Therapeutic Opportunities for Small Molecule Modulators of Chemokine Receptors
Dr. Thomas J. SCHALL
(CHEMOCENTRYX, Mountain View, United States)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Graham WARRELLOW
(UCB SA, Cambridge, United Kingdom)
Eg5 Inhibitors
Dr. Christopher COX
(MERCK RESEARCH LABORATORIES, West Point, United States)
Allosteric Akt Inhibitors
Dr. George HARTMANN
(MERCK RESEARCH LABORATORIES, West-Point, United States)
PLK1 Inhibitor (BI-2536)
Dr. Matthias HOFFMANN
(BOEHRINGER INGELHEIM, Biberach, Germany)

Session Chair
Dr. Katerina LEFTHERIS
(BRISTOL-MYERS SQUIBB, Princeton, NJ, United States)
Current Aspects and Future Trends in Immunomodulation
Dr. Murray MCKINNON
(BRISTOL-MYERS SQUIBB, Princeton, United States)
Advances in Targeting Glucocorticoids
Dr. Hartmut REHWINKEL
(SCHERING, Berlin, Germany)
Oral communication
to be selected from submitted abstracts

16. Antispsychotic Targets 17. Antivirals 18. Pain

Session Chair
Prof. Klaus P. BOGESO
(H. LUNDBECK, Valby, Denmark)
NK3 Receptors
Prof. Klaus SIMONSEN
(H. LUNDBECK, Valby, Denmark)
PDE10 Inhibitors
Dr. Patrick Robert VERHOEST
(PFIZER GLOBAL RESEARCH, Groton, United States)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Maria Jose CAMARASA
(SEQT, Madrid, Spain)
Title to be determined
Dr. Jan BALZARINI
(REGA INSTITUTE FOR MEDICAL RESEARCH, Leuven, Belgium)
Lethal Mutagenesis as a New Antiviral Strategy
Prof. Esteban DOMINGO
(UNIVERSIDAD AUTONOMA DE MADRID, Madrid, Spain)
Oral communication
to be selected from submitted abstracts

Session Chair
Dr. Mark DUGGAN
(AMGEN, Cambridge, United States)
Title to be determined
Dr. Stefan MCDONOUGH
(AMGEN, Cambridge, United States)
Nav1.7 Inhibitors – Discovery and Development
Dr. Joseph L. DUFFY
(MERCK RESEARCH LABORATORIES, Rahway, United States)
Oral communication
Dr. Graham N. MAW
(PFIZER, Sandwich, United Kingdom)

19. Exploring the Chemical Space 20. Chemokines 21. Systems Level Research Informs Drug Target Identification and Therapy Design

Session Chair
Profs. Herbert WALDMANN & STEFAN WETZEL
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)
Title to be determined
Prof. Gisbert SCHNEIDER
(JOHANN WOLFGANG GOETHE UNIVERSITY, Frankfurt, Germany)
Title to be determined
Dr. Antonio MACCHIARULO
(UNIVERSITY OF PERUGIA, Perugia, Italy)
Title to be determined
Prof. Jean-Louis REYMOND
(UNIVERSITÄT BERN, Bern, Switzerland)
Title to be determined
Dr. Stefan WETZEL
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)

Session Chair
Prof. Gerhard ECKER
(UNIVERSITY OF VIENNA & EFMC, Vienna, Austria)
Title to be determined
Prof. Nobutaka FUJII
(KYOTO UNIVERSITY, Kyoto, Japan)
Selective Dual CCR2/5 Antagonists
Dr. Wolfgang MILTZ
(NOVARTIS PHARMA, Basel, Switzerland)
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Harel WEINSTEIN
(CORNELL UNIVERSITY, New York, United States)
Drug Discovery, Drug Delivery and Therapeutic Monitoring by Molecular, Cellular and Functional Imaging of Atherothrombosis
Dr. Zahi A. FAYAD
(MOUNT SINAI SCHOOL OF MEDICINE, New York, United States)
Understanding Drug Mechanisms and Designing Therapy at the Systems Level of the Functional Human Interactome
Prof. Gianni CESARENI
(UNIVERSITY OF ROME ‘TOR VERGATA’, Rome, Italy)
Special Structural, Dynamic and Functional Characteristics of Membrane Proteins and their Signaling Partners that Determine the Mode and Putative Success of Therapy Design Targeting Cellular Signaling Systems.
Prof. Harel WEINSTEIN
(CORNELL UNIVERSITY, New York, United States)

22. New Computational Approaches Supporting Drug Design 23. Druggability of Protein-Protein Interactions 24. Systems Biology and Medicinal Chemistry

Session Chair
Dr. Jordi MESTRES
(IMIM AND UNIVERSITAT POMPEU FABRA, Barcelona, Spain)
Overview on New Computational Tools Supporting Drug Design
Prof. Tudor I. OPREA
(UNIVERSITY OF NEW MEXICO, Albuquerque, United States)
Novel Tools for Data Gathering
Dr. Muthukumarasamy KARTHIKEYAN
(NATIONAL CHEMICAL LABORATORY, Pune, India)
Novel Tools for Data Classification
Dr. Ansgar SCHUFFENHAUER
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Novel Tools for Data Exploitation
Dr. Elisabet GREGORI-PUIGJANE
(CHEMOTARGETS, Barcelona, Spain)

Session Chair
Dr. Peter NUSSBAUMER
(NOVARTIS, Vienna, Austria)
Title to be determined
Dr. Leonard J. PAGLIARO
(BIOIMAGE, Soeborg, Denmark)
Oral communication
to be selected from submitted abstracts
Oral communication
to be selected from submitted abstracts
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Christian NOE
(UNIVERSITY OF VIENNA, Vienna, Austria)
Network Based Drug Discovery
Prof. Hans WESTERHOFF
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)
Title to be determined
Prof. Christian NOE
(UNIVERSITY OF VIENNA, Vienna, Austria)
Oral communication
to be selected from submitted abstracts

25. Structure Based Drug Design (AFMC) 26. Modulators of Adenosine and P2Y Receptors 27. Addressing Therapeutic Complexity in Oncology with Med. Chem.

Session Chair
Prof. Esin AKI-SENER
(ANKARA UNIVERSITY, Ankara, Turkey)
Quantum Chemical Calculation of Protein-Ligand Interaction
Prof. Isao NAKANISHI
(KYOTO UNIVERSITY, Kyoto, Japan)
Title to be determined
Dr. Jose VARGHESE
(CSIRO, Parkville, Australia)
Oral communication
to be selected from submitted abstracts

Session Chair
Prof. Kenneth A. JACOBSON
(NIDDK, Bethesda, United States)
Engineering of Purine Receptors and Their Ligands
Prof. Kenneth A. JACOBSON
(NIDDK, Bethesda, United States)
Title to be determined
Prof. Pier Giovanni BARALDI
(UNIVERSITY OF FERRARA, Ferrara, Italy)
Allosteric Modulation of Purine Receptors
Prof. Ad P. IJZERMAN
(LEIDEN/AMSTERDAM CENTER FOR DRUG RESEARCH, Leiden, The Netherlands)

Session Chair
Dr. Graeme ROBERTSON
(SIENA BIOTECH, Siena, Italy)
Alternatives to Kinase Inhibitors for Cancer Therapies
Prof. Giovanni GAVIRAGHI
(SIENA BIOTECH, Siena, Italy)
Endothelin Converting Enzyme Inhibitors as Anticancer Agents for Human Glioblastoma. A Comparison with Endothelin Receptor Antagonists
Dr. Lucienne JUILLERAT
(CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS, Lausanne, Switzerland)
Novel Kinase Inhibitors
Dr. Dirk HEERDING
(GLAXOSMITHKLINE, Collegeville, United States)

Read More →
Share: